Pteridines. 41. Synthesis and dihydrofolate reductase inhibitory activity of some cycloalka[g]pteridines. 1977

E C Taylor, and J V Berrier, and A J Coccuzza, and R Kobylecki, and J J McCormack

A number of homologous 2,4-diaminocycloalka[g]pteridines varying in ring size from 5 to 15 were prepared by (a) condensation of aminomalononitrile tosylate with alpha-oximinocycloalkanones, deoxygenation of the resulting 2-amino-3-cyanocycloalka[b]pyrazine 1-oxides, and guanidine cyclization; (b) guanidine cyclization of the above pyrazine 1-oxides to give 2,4-diaminocycloalka[g]pteridine 8-oxides, followed by deoxygenation; or (c) condensation of 2,4,5,6-tetraaminopyrimidine with a cycloalka-1,2-dione (for the cyclohepta- and cycloocta[g]pteridines only). These compounds were examined for their activity as dihydrofolate reductase inhibitors against Lactobacillus casei, rat liver, L1210, and Trypanosoma cruzi. Activity was found to depend upon ring size, with the greatest activity exhibited by the cyclododeca derivatives 31.

UI MeSH Term Description Entries
D007780 Lacticaseibacillus casei A rod-shaped bacterium isolated from milk and cheese, dairy products and dairy environments, sour dough, cow dung, silage, and human mouth, human intestinal contents and stools, and the human vagina. L. casei is CATALASE positive. Lactobacillus casei
D007939 Leukemia L1210 An experimental LYMPHOCYTIC LEUKEMIA of mice. Leukemia L 1210,L 1210, Leukemia,L1210, Leukemia
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D011621 Pteridines Compounds based on pyrazino[2,3-d]pyrimidine which is a pyrimidine fused to a pyrazine, containing four NITROGEN atoms. 1,3,5,8-Tetraazanaphthalene,Pteridine,Pteridinone,Pyrazino(2,3-d)pyrimidine,Pyrazinopyrimidine,Pyrazinopyrimidines,Pyrimido(4,5-b)pyrazine,Pteridinones
D005493 Folic Acid Antagonists Inhibitors of the enzyme, dihydrofolate reductase (TETRAHYDROFOLATE DEHYDROGENASE), which converts dihydrofolate (FH2) to tetrahydrofolate (FH4). They are frequently used in cancer chemotherapy. (From AMA, Drug Evaluations Annual, 1994, p2033) Antifolate,Antifolates,Dihydrofolate Reductase Inhibitor,Folic Acid Antagonist,Dihydrofolate Reductase Inhibitors,Folic Acid Metabolism Inhibitors,Acid Antagonist, Folic,Acid Antagonists, Folic,Antagonist, Folic Acid,Antagonists, Folic Acid,Inhibitor, Dihydrofolate Reductase,Inhibitors, Dihydrofolate Reductase,Reductase Inhibitor, Dihydrofolate,Reductase Inhibitors, Dihydrofolate
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus

Related Publications

E C Taylor, and J V Berrier, and A J Coccuzza, and R Kobylecki, and J J McCormack
May 1972, Journal of medicinal chemistry,
E C Taylor, and J V Berrier, and A J Coccuzza, and R Kobylecki, and J J McCormack
May 1973, Journal of medicinal chemistry,
E C Taylor, and J V Berrier, and A J Coccuzza, and R Kobylecki, and J J McCormack
June 1974, Archiv der Pharmazie,
E C Taylor, and J V Berrier, and A J Coccuzza, and R Kobylecki, and J J McCormack
November 2008, European journal of medicinal chemistry,
E C Taylor, and J V Berrier, and A J Coccuzza, and R Kobylecki, and J J McCormack
June 1986, Journal of medicinal chemistry,
E C Taylor, and J V Berrier, and A J Coccuzza, and R Kobylecki, and J J McCormack
December 2021, Molecules (Basel, Switzerland),
E C Taylor, and J V Berrier, and A J Coccuzza, and R Kobylecki, and J J McCormack
December 2008, Bioorganic & medicinal chemistry letters,
E C Taylor, and J V Berrier, and A J Coccuzza, and R Kobylecki, and J J McCormack
May 2024, Scientific reports,
E C Taylor, and J V Berrier, and A J Coccuzza, and R Kobylecki, and J J McCormack
October 1974, British journal of haematology,
E C Taylor, and J V Berrier, and A J Coccuzza, and R Kobylecki, and J J McCormack
August 1996, Chemical & pharmaceutical bulletin,
Copied contents to your clipboard!